Tadokoro J

Chronic idiopathic myelofibrosis expressing a novel type of TEL - PDGFRB chimaera responded to imatinib mesylate therapy

Chronic idiopathic myelofibrosis expressing a novel type of TEL - PDGFRB chimaera responded to imatinib mesylate therapy

Low Frequency of BCL10 Gene Mutations in B-Cell Non-Hodgkin’s Lymphoma

TheBCL10 gene was identified at the breakpoint region of the t(1;14)(p22;q32) translocation in mucosa-associated lymphoid tissue lymphoma. Initially, mutations in theBCL10 gene were reported to occur at a high frequency in various types of lymphomas and solid tumors. However, subsequent studies showed that the mutations were rarely recognized.To evaluate the frequency and spectrum of its mutations in B-cell non-Hodgkin’s lymphoma (B-NHL), we screened 56 cases with B-NHL by mutation analysis of exons 2 and 3 of the gene. In addition to 2 polymorphisms, a frame-shift mutation and a missense mutation were identified in 2 cases (3.6%): 1 with diffuse large B-cell lymphoma and the other with mantle cell lymphoma. Both cases showed mutations within exon 3, resulting in a C-terminal truncation in the former and a C-terminal amino acid substitution in the latter. Reverse transcriptase-polymerase chain reaction analysis of the former case revealed that both the mutated and the wild-type alleles were transcribed with or without a sequence modification. Our results, together with recent reports, indicate thatBCL10 gene mutations take place in a small population of B-NHL and are not associated with specific histological subtypes.